<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Glob J Health Sci</journal-id><journal-id journal-id-type="iso-abbrev">Glob J Health Sci</journal-id><journal-title-group><journal-title>Global Journal of Health Science</journal-title></journal-title-group><issn pub-type="ppub">1916-9736</issn><issn pub-type="epub">1916-9744</issn><publisher><publisher-name>Canadian Center of Science and Education</publisher-name><publisher-loc>Canada</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26153197</article-id><article-id pub-id-type="pmc">4803840</article-id><article-id pub-id-type="publisher-id">GJHS-7-1</article-id><article-id pub-id-type="doi">10.5539/gjhs.v7n7p1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Effects of Synbiotics on Inflammatory Markers in Patients With Type 2 Diabetes Mellitus</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kooshki</surname><given-names>A. Akram</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tofighiyan</surname><given-names>Tahereh</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Rakhshani</surname><given-names>Mohamad Hassan</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1"><label>1</label>School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran</aff><aff id="aff2"><label>2</label>School of Nursing, Sabzevar University of Medical Sciences, Sabzevar, Iran</aff><aff id="aff3"><label>3</label>School of Health Sciences, Sabzevar University of Medical Sciences, Sabzevar, Iran</aff><author-notes><corresp id="cor1">
Correspondence: Tahereh Tofighiyan, School of Nursing, Sabzevar University of Medical Sciences, Sabzevar, Iran. E-mail: <email xlink:href="tofighiyan260@gmail.com">tofighiyan260@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>26</day><month>3</month><year>2015</year></pub-date><volume>7</volume><issue>7</issue><fpage>1</fpage><lpage>5</lpage><history><date date-type="received"><day>02</day><month>12</month><year>2014</year></date><date date-type="accepted"><day>28</day><month>1</month><year>2015</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Canadian Center of Science and Education</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p><!--CREATIVE COMMONS-->This is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>).</license-p></license></permissions><abstract><sec id="st1"><title>Introduction:</title><p>With regard to the relationship between inflammation and insulin resistance and due to the lack of researches conducted about the effect of synbiotics on inflammatory markers in diabetes patients, this study was designed to investigate the effect of these markers.</p></sec><sec id="st2"><title>Methods:</title><p>A double-blind, placebo-controlled trial was conducted among 44 type 2 diabetes patients. They were randomized to symbiotic or placebo group. Patients in the symbiotic group received one symbiotic tablet daily for 8 weeks whereas the placebo group received 1 placebo tablet. The hs-CRP concentration, TNF-&#x003b1; and IL-6 were measured by using ELISA kits. The dietary intakes of patients were assessed at the first and the end of the study and analyzed by Nutritionist IV. Data were analyzed by using SPSS 16.0 via paired and independent t- test.</p></sec><sec id="st3"><title>Results:</title><p>Anthropometric and dietary data were not significantly different between the two groups at the first and the end of the study. The serum concentrations of hs-CRP, IL-6 and TNF-&#x003b1; decreased significantly in the symbiotic group at the end of week 8 compared to baseline (p&#x0003c;0.05). Also, no significant changes were seen in the placebo group (p&#x0003e;0.05). The reduction in inflammatory markers in the symbiotic group were significant in compared to the placebo group (P&#x0003c;0.05).</p></sec><sec id="st4"><title>Conclusions:</title><p>Symbiotic supplementation can reduce serum hs-CRP, IL-6 and TNF-&#x003b1; concentrations, a risk factor for cardiovascular diseases.</p></sec></abstract><kwd-group><kwd>symbiotic</kwd><kwd>inflammation</kwd><kwd>type 2 diabetes mellitus</kwd></kwd-group></article-meta></front><body><sec id="sec1-1"><title>1. Introduction</title><p>Diabetes mellitus type 2 is an impendent risk factor for morbidity and mortality of cardiovascular diseases. Relative risk of cardiovascular disease is 2-3 times high in diabetic men and 3-4 times in diabetic women comparison to non-diabetic controls (<xref rid="ref3" ref-type="bibr">Barrett et al., 1991</xref>; <xref rid="ref22" ref-type="bibr">Steven et al., 1998</xref>; <xref rid="ref24" ref-type="bibr">William et al., 1979</xref>). Risk factors for cardiovascular diseases such as lipid abnormalities and hypertensions are prevalent in diabetic patients but they cannot explain the high frequency of cardiovascular disease in these patients (<xref rid="ref21" ref-type="bibr">Stenvinkel et al., 2004</xref>). Some studies have indicated that high concentrations of serum inflammation markers are an important risk factor for cardiovascular disease in type&#x02019;s diabetes patients (<xref rid="ref18" ref-type="bibr">Reaven et al., 1988</xref>; <xref rid="ref6" ref-type="bibr">Defronzo et al., 1991</xref>; <xref rid="ref7" ref-type="bibr">Despres et al., 1996</xref>). Few reports are available on the correlation between hs-C-reactive protein (hs-CRP) and cardiovascular disease in type 2 diabetes patnts (<xref rid="ref11" ref-type="bibr">Japer et al., 1999</xref>; <xref rid="ref20" ref-type="bibr">Stehouwer et al., 2002</xref>). Also, tumor necrosis factor-&#x003b1; (TNF-&#x003b1;) is an inflammatory cytokine that can alter in sensitivity in different ways by attenuating insulin receptor Signaling pathways, by decreasing glucose transporter &#x02013; 4 in adiposities and by suppressing adiponectin (<xref rid="ref5" ref-type="bibr">Calle et al., 2012</xref>). Also, TNF-&#x003b1; increases the expression of genes encoding IL-6 and Mcp-1 and contributes to the progression of atherosclerosis (<xref rid="ref5" ref-type="bibr">Calle et al., 2012</xref>).</p><p>Interleukin- 6 (IL-6) is inflammatory markers that the main its effects is the induction of hepatic CRP production which to be an independent, major risk factor for cardiovascular disease (<xref rid="ref19" ref-type="bibr">Ridker et al., 2003</xref>). Recent studies have proposed that IL-6 could be involved in insulin resistance and diabetes and its complications (<xref rid="ref4" ref-type="bibr">Bastard et al., 2006</xref>; <xref rid="ref17" ref-type="bibr">Ray et al., 2009</xref>).</p><p>Some studies were done to find treatment ways for lowing inflammation in diabetes patients (<xref rid="ref1" ref-type="bibr">Alokail et al., 2013</xref>). Although, limited studies have been done on the effects of probiotic and synbiotic supplementation on serum systemic inflammation markers such as CRP, IL-6 and TNF-&#x003b1; in patients with type2 diabetes (<xref rid="ref12" ref-type="bibr">Kootte et al., 2012</xref>; <xref rid="ref15" ref-type="bibr">Musso et al., 2011</xref>). The finding of these studies have been contradictory.</p></sec><sec id="sec1-2"><title>2. Methods</title><sec id="sec2-1"><title>2.1 Data Source and Study Population</title><p>This study was a randomized double-blind, placebo- controlled trial. Forty-four type 2 diabetic patients (16 men and 28 women) were recruited from diabetic patients of diabetes clinic of Vaseei Hospital in Sabzevar, Iran. Type 2 diabetes was diagnosed according to the criteria of world health organization (<xref rid="ref25" ref-type="bibr">World Health organization., 1985</xref>). The patients in this study did not have inflammatory and infectious diseases including hepatitis, and none of them received probiotic and prebiotic and omega-3 fatty acids and L-carnitine supplement and steroidal and non-steroidal anti-inflammatory drugs. Participating were received metformin, glybenglamide and insuline for controlling blood sugar. During this study, the diabetic patients, type and dose of drugs did not altered for any of the patients.</p><p>Patients were randomized to symbiotic (pre and probiotic) or placebo group subjects in the symbiotic group received one symbiotic tablet daily for 8 weeks and the placebo group received 1 placebo tablet.</p><p>Patients were advised no change in their dietary habits, physical activities and drug regiments. At the first and the end of study, 5ml blood was collected from each patient after a 12- to 14-h fast. Blood samples after clotting at room temperature (20-25 &#x000b0;C) were centrifuged at 2000 rpm for 10 min. The sera were separated into small aliquots and frozen at -70 &#x000b0;C until they were used.</p><p>The serum hs-CRP concentration was determined by using enzyme-like immune-sorbent assay (ELISA) kits (Monobind, Inc., Lake Forest, Calif., USA). The CV for serum CRP was 2.9%. Serum TNF-&#x003b1; and IL-6 were measured by using ELISA kits (Diaclone, Beancon, France). The CVs for serum TNF-&#x003b1; and IL-6 were 5.6% and 5.1% respectively.</p><p>Patients were weighted and heighted at baseline and at the end of week 8. In addition, the dietary intakes of patients were assessed using a 2-day food recall at the first and at the end of study. Subject&#x02019;s diets were analyzed by Nutritionist IV software (N squared computing, san Bruno, Calif., USA).</p><p>To ascertainment of subjects&#x02019; compliance, we provided each patient with a fixed number of tablets and instructions to return the unconsumed tablets at the end of the study. The compliance rate for each patient was determined according to the number of returned tablets. The compliance of all subjects was more than 90% and no adverse events were reported.</p></sec><sec id="sec2-2"><title>2.2 Statistical Analysis</title><p>Statistical analysis of the data was performed by using statistical package for the social sciences (SPSS, Inc., Chicago, III., USA) for windows version 15. As all quantitative parameters were normally distributed according to the Kolmogorov-Smirnov test, we used the t-test and the paired t-test to compare parameters between and within groups, respectively. The differences were considered significant at P&#x0003c;0.05.</p></sec><sec id="sec2-3"><title>2.3 Ethnics</title><p>The study protocol was approved by the Ethics committee of Sabzevar University of Medical Sciences. This study was in adherence with the Declaration of Helsinki Written informed consent which was obtained from all patients.</p></sec></sec><sec id="sec1-3"><title>3. Results</title><p>The patients&#x02019; baseline characteristics did not differ significantly between the two groups (<xref ref-type="table" rid="T1">Table 1</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Baseline characteristics and anthropometric data of diabetic patients in the symbiotic and placebo groups</p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Characterisfics</th><th align="left" rowspan="1" colspan="1">Symbiotic(n=22)</th><th align="left" rowspan="1" colspan="1">Placebo(n=22)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Age (years)</bold></td><td align="left" rowspan="1" colspan="1">53.45&#x000b1; 10.8</td><td align="left" rowspan="1" colspan="1">54.5 &#x000b1; 11.10</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Duration (months)</bold></td><td align="left" rowspan="1" colspan="1">7.25&#x000b1; 5.2</td><td align="left" rowspan="1" colspan="1">7.45&#x000b1; 5.4</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Sex</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Men, n</bold></td><td align="left" rowspan="1" colspan="1">8(36.36%)</td><td align="left" rowspan="1" colspan="1">8(36.36%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Women, n</bold></td><td align="left" rowspan="1" colspan="1">14(63.63%)</td><td align="left" rowspan="1" colspan="1">14(63.63%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Smoker, n</bold></td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>BMI, Kg/m<sup>2</sup></bold></td><td align="left" rowspan="1" colspan="1">22.79&#x000b1;2.7</td><td align="left" rowspan="1" colspan="1">22.47&#x000b1; 2.38</td></tr></tbody></table></table-wrap><p>Anthropometric and dietary data were not statistically different between the two groups at the baseline and the end of the study. In addition, these factors did not significantly change within each group during the study.</p><p>The serum concentrations of hs-CRP, IL-6 and TNF-&#x003b1; decreased significantly in the symbiotic group at the end of the study compared to the first study (p&#x0003c;0.05). Also, no significant changes were observed in the placebo group (p&#x0003e;0.05). The reduction in serum concentrations of hs-CRP, IL-6 and TNF-&#x003b1; in the symbiotic group were significant in compared to the placebo group (P&#x0003c;0.05, <xref ref-type="table" rid="T2">Table 2</xref>).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>serum concentrations of hs-CRP, IL-6 and TNF- &#x003b1; in the symbiotic and placebo groups (n=22 for all values)</p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Serum parameter and groups</th><th align="left" rowspan="1" colspan="1">Baseline</th><th align="left" rowspan="1" colspan="1">Week8</th><th align="left" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1"><bold>hs-CRP, mg/L</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Synbiotic</bold></td><td align="left" rowspan="1" colspan="1">4.94&#x000b1; 2.36</td><td align="left" rowspan="1" colspan="1">4.15&#x000b1; 1.96</td><td align="left" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Placebo</bold></td><td align="left" rowspan="1" colspan="1">5.00&#x000b1; 2.31</td><td align="left" rowspan="1" colspan="1">5.08&#x000b1; 2.27</td><td align="left" rowspan="1" colspan="1">0.412</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>IL- 6, ng/L</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Synbiotic</bold></td><td align="left" rowspan="1" colspan="1">9.19&#x000b1; 5.97</td><td align="left" rowspan="1" colspan="1">8.12&#x000b1; 5.02</td><td align="left" rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Placebo</bold></td><td align="left" rowspan="1" colspan="1">8.89&#x000b1; 5.18</td><td align="left" rowspan="1" colspan="1">8.86&#x000b1; 5.03</td><td align="left" rowspan="1" colspan="1">0.489</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>TNF-&#x003b1;, ng/L</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Sybiotic</bold></td><td align="left" rowspan="1" colspan="1">8.03&#x000b1; 2.73</td><td align="left" rowspan="1" colspan="1">7.36&#x000b1; 2.61</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Placebo</bold></td><td align="left" rowspan="1" colspan="1">8.64&#x000b1; 2.61</td><td align="left" rowspan="1" colspan="1">8.65&#x000b1; 2.57</td><td align="left" rowspan="1" colspan="1">0.956</td></tr></tbody></table></table-wrap></sec><sec id="sec1-4"><title>4. Discussion</title><p>Systemic inflammation is a common in the diabetes patients (<xref rid="ref7" ref-type="bibr">Despres et al., 1996</xref>). It may lead to various complications including the cardiovascular disease in diabetes patients. Also, no treatment strategy for reducing inflammation in diabetes patients has been established yet (<xref rid="ref5" ref-type="bibr">Calle et al., 2012</xref>).</p><p>In the present study, symbiotic supplementation significantly decreased serum hs-CRP, IL-6 and TNF-&#x003b1;. There is disagreement on the effect of synbiotic on serum systematic inflammation marker in diabetic patients.</p><p>Evidence is available on the anti inflammatory properties of probiotics. Some researches showed beneficial of probiotic using in diabetes type 2 but (<xref rid="ref1" ref-type="bibr">Alokail et al., 2013</xref>) others reported no effect (<xref rid="ref8" ref-type="bibr">Diamant et al., 2011</xref>; <xref rid="ref9" ref-type="bibr">Esteve et al., 2011</xref>). Hatakka et al. showed that Lactobacillus rhamnosus GG increased serum IL-1B and no effect on IL-6 and TNF-&#x003b1; and IL-10 (<xref rid="ref10" ref-type="bibr">Hatakka et al., 2003</xref>).</p><p>In contrast, Marschan and et al showed that infants receiving probiotic had higher plasma levels of CRP and IL-10 comparison to group placebo (<xref rid="ref13" ref-type="bibr">Marschan et al., 2008</xref>).</p><p>Asemi et al., showed that daily administration of multispecies probiotic supplements decreased in serum hs-CRP in diabetes patient in 8 weeks but in their study, effects of probiotc supplements was not evaluated on serum IL-6 and TNF-&#x003b1; (<xref rid="ref2" ref-type="bibr">Asemi et al.,2013</xref>).</p><p>CRP and IL-6, the two most sensitive markers of inflammation have been elevated in patients with type 2 diabetes (<xref rid="ref16" ref-type="bibr">Pickup et al., 1997</xref>).</p><p>Also, high CRP level is reported to be a risk factor for progression type 2 diabetes (<xref rid="ref23" ref-type="bibr">Voulgari et al., 2006</xref>).</p><p>Mazloom and et al indicated that administration of 1500 mg probiotic capsules twice daily to 20 patients with type2 diabets for 6 weeks reduced serum IL-6 and elevated serum hs-CRP levels although not statistically significant(<xref rid="ref14" ref-type="bibr">Mazloom et al.,2013</xref>).</p></sec><sec id="sec1-5"><title>5. Conclusion</title><p>In conclusion, symbiotic supplementation can reduce serum hs-CRP, IL-6 and TNF-&#x003b1; concentrations, a risk factor for cardiovascular diseases.</p></sec></body><back><ack><title>Acknowledgements</title><p>This study was supported by Sabzevar University of Medical Sciences of Sabzevar of Iran. The authors thank the staff and of diabetic clinic for valuable assistance the authors also grate fully acknowledge the cooperation of the participating patients.</p></ack><fn-group><fn fn-type="other"><p><bold>Disclosure</bold></p><p>The authors affirm that they have no conflict of interest to declare.</p></fn></fn-group><ref-list><title>References</title><ref id="ref1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alokail</surname><given-names>M</given-names></name><name><surname>Sabico</surname><given-names>Sh</given-names></name><name><surname>Al-Saleh</surname><given-names>Y</given-names></name><name><surname>Al-Daghri</surname><given-names>N. M</given-names></name><name><surname>Alkharfy</surname><given-names>Kh. M</given-names></name><name><surname>Vanhoutte</surname><given-names>P. M</given-names></name><etal/></person-group><article-title>Effects of probiotics in patients with diabetes mellitus type2: study protocol for a randomized double-blind, placebo-controlled trial</article-title><source>Trails</source><year>2013</year><volume>14</volume><fpage>195</fpage><lpage>203</lpage><comment><uri xlink:type="simple" xlink:href="http://dx.doi.org/10.1186/1745-6215-14-195">http://dx.doi.org/10.1186/1745-6215-14-195</uri></comment></element-citation></ref><ref id="ref2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asemi</surname><given-names>Z</given-names></name><name><surname>Zare</surname><given-names>Z</given-names></name><name><surname>Shakeri</surname><given-names>H</given-names></name><name><surname>Sabihi</surname><given-names>S. S</given-names></name><name><surname>Esmaillzadeh</surname><given-names>A</given-names></name></person-group><article-title>Effect of Multispecies probiotic supplements on metabolic profiles, hs-CRP and oxidative stress in patients with type 2 Diabetes</article-title><source>Ann Nutr Metab</source><year>2013</year><volume>63</volume><issue>1-2</issue><fpage>1</fpage><lpage>9</lpage><comment><uri xlink:type="simple" xlink:href="http://dx.doi.org/10.1159/000349922">http://dx.doi.org/10.1159/000349922</uri></comment><pub-id pub-id-type="pmid">23899653</pub-id></element-citation></ref><ref id="ref3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett-Connor</surname><given-names>E. L</given-names></name><name><surname>Cohn</surname><given-names>B. A</given-names></name><name><surname>Wingard</surname><given-names>D. L</given-names></name><name><surname>Edelstein</surname><given-names>S. L</given-names></name></person-group><article-title>Why is diabetemellitus a stronger risk factor for fatal ischemic heart disease in womenthan in men? The Rancho Bernardo Study</article-title><source>JAMA</source><year>1991</year><volume>265</volume><fpage>627</fpage><lpage>631</lpage><comment><uri xlink:type="simple" xlink:href="http://dx.doi.org/10.1001/jama.1991.03460050081025">http://dx.doi.org/10.1001/jama.1991.03460050081025</uri></comment><pub-id pub-id-type="pmid">1987413</pub-id></element-citation></ref><ref id="ref4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bastard</surname><given-names>J. P</given-names></name><name><surname>Maachi</surname><given-names>M</given-names></name><name><surname>Lagathu</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>M. J</given-names></name><name><surname>Caron</surname><given-names>M</given-names></name><name><surname>Vidal</surname><given-names>H</given-names></name><etal/></person-group><article-title>Recent advances in relationship between obesity, inflammation and insulin resistance</article-title><source>Eur cytokine Netw</source><year>2006</year><volume>17</volume><issue>1</issue><fpage>4</fpage><lpage>12</lpage><comment>PMID PubMed: 16613757</comment><pub-id pub-id-type="pmid">16613757</pub-id></element-citation></ref><ref id="ref5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calle</surname><given-names>M. C</given-names></name><name><surname>Fernandez</surname><given-names>M. L</given-names></name></person-group><article-title>Inflammation and type 2 diabetes</article-title><source>Diabetes Metabolism</source><year>2012</year><volume>38</volume><fpage>183</fpage><lpage>191</lpage><comment><uri xlink:type="simple" xlink:href="http://dx.doi.org/10.1016/j.diabet.2011.11.006">http://dx.doi.org/10.1016/j.diabet.2011.11.006</uri></comment><pub-id pub-id-type="pmid">22252015</pub-id></element-citation></ref><ref id="ref6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Defronzo</surname><given-names>R. A</given-names></name><name><surname>Ferannini</surname><given-names>E</given-names></name></person-group><article-title>Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hyper tension, dyslipidemia and atherosclerotic cardiovascular disease</article-title><source>Diabetes care</source><year>1991</year><volume>14</volume><fpage>173</fpage><lpage>194</lpage><comment>PMID PubMed: 2044434</comment><comment><uri xlink:type="simple" xlink:href="http://dx.doi.org/10.2337/diacare.14.3.173">http://dx.doi.org/10.2337/diacare.14.3.173</uri></comment><pub-id pub-id-type="pmid">2044434</pub-id></element-citation></ref><ref id="ref7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Despres</surname><given-names>J. P</given-names></name><name><surname>Lamarch</surname><given-names>B</given-names></name><name><surname>Mauriege</surname><given-names>P</given-names></name><name><surname>Cantin</surname><given-names>B</given-names></name><name><surname>Dagenais</surname><given-names>G</given-names></name><name><surname>Moorgani</surname><given-names>S</given-names></name><etal/></person-group><article-title>Hyperinsulinemia as an independent risk factor for ischemic heart disease</article-title><source>N Engl J Med</source><year>1996</year><volume>334</volume><fpage>952</fpage><lpage>958</lpage><comment><uri xlink:type="simple" xlink:href="http://dx.doi.org/10.1056/NEJM199604113341504">http://dx.doi.org/10.1056/NEJM199604113341504</uri></comment><pub-id pub-id-type="pmid">8596596</pub-id></element-citation></ref><ref id="ref8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamant</surname><given-names>M</given-names></name><name><surname>Blaak</surname><given-names>E. E</given-names></name><name><surname>de Vos</surname><given-names>W. M</given-names></name></person-group><article-title>Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes?</article-title><source>Obes Rev</source><year>2011</year><volume>12</volume><fpage>272</fpage><lpage>281</lpage><comment><uri xlink:type="simple" xlink:href="http://dx.doi.org/10.1111/j.1467-789X.2010.00797.x">http://dx.doi.org/10.1111/j.1467-789X.2010.00797.x</uri></comment><pub-id pub-id-type="pmid">20804522</pub-id></element-citation></ref><ref id="ref9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esteve</surname><given-names>E</given-names></name><name><surname>Ricart</surname><given-names>W</given-names></name><name><surname>Fernandez-Real</surname><given-names>J. M</given-names></name></person-group><article-title>Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiota coevolve with insulin resistance?</article-title><source>Curr Opin Clin Nutr Metab Care</source><year>2011</year><volume>14</volume><fpage>483</fpage><lpage>490</lpage><comment><uri xlink:type="simple" xlink:href="http://dx.doi.org/10.1097/MCO.0b013e328348c06d">http://dx.doi.org/10.1097/MCO.0b013e328348c06d</uri></comment><pub-id pub-id-type="pmid">21681087</pub-id></element-citation></ref><ref id="ref10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatakka</surname><given-names>K</given-names></name><name><surname>Martio</surname><given-names>J</given-names></name><name><surname>Korpela</surname><given-names>M</given-names></name><name><surname>Herranen</surname><given-names>M</given-names></name><name><surname>Poussa</surname><given-names>T</given-names></name><name><surname>Laasanen</surname><given-names>T</given-names></name><etal/></person-group><article-title>Effects of probiotic therapy on the activity and activation of mild rheumatoid arthritis-a pilot study</article-title><source>Scand J Rheumatol</source><year>2003</year><volume>32</volume><issue>4</issue><fpage>211</fpage><lpage>215</lpage><comment>PMID PubMed: 14626627</comment><comment><uri xlink:type="simple" xlink:href="http://dx.doi.org/10.1080/03009740310003695">http://dx.doi.org/10.1080/03009740310003695</uri></comment><pub-id pub-id-type="pmid">14626627</pub-id></element-citation></ref><ref id="ref11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Japer</surname><given-names>A</given-names></name><name><surname>Hinsvergh</surname><given-names>V. W. M</given-names></name><name><surname>kostense</surname><given-names>P. J</given-names></name><name><surname>Emeis</surname><given-names>J. J</given-names></name><name><surname>Yudkin</surname><given-names>J. S</given-names></name><name><surname>Nijpels</surname><given-names>G</given-names></name><etal/></person-group><article-title>Von Willebr and factor, C-reactive protein and 5-year mortality in diabetic and non-diabetic subjects</article-title><source>The Hoorn study Arterioscl Tromb Vasc Biol</source><year>1999</year><volume>19</volume><fpage>3071</fpage><lpage>3078</lpage><comment><uri xlink:type="simple" xlink:href="http://dx.doi.org/10.1161/01.ATV.19.12.3071">http://dx.doi.org/10.1161/01.ATV.19.12.3071</uri></comment></element-citation></ref><ref id="ref12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kootte</surname><given-names>R. S</given-names></name><name><surname>Vrieze</surname><given-names>A</given-names></name><name><surname>Holleman</surname><given-names>F</given-names></name><name><surname>Dallinga-Thie</surname><given-names>G. M</given-names></name><name><surname>Zoetenda</surname><given-names>E. G</given-names></name><name><surname>de Vos</surname><given-names>W. M</given-names></name><etal/></person-group><article-title>The therapeutic potential of manipulationg gut microbiota in obesity and type 2 diabetes mellitus</article-title><source>Diabetes Obes Metab</source><year>2012</year><volume>14</volume><fpage>112</fpage><lpage>120</lpage><comment><uri xlink:type="simple" xlink:href="http://dx.doi.org/10.1111/j.1463-1326.2011.01483.x">http://dx.doi.org/10.1111/j.1463-1326.2011.01483.x</uri></comment><pub-id pub-id-type="pmid">21812894</pub-id></element-citation></ref><ref id="ref13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marschan</surname><given-names>E</given-names></name><name><surname>Kuitunen</surname><given-names>M</given-names></name><name><surname>Kukkonen</surname><given-names>k</given-names></name><name><surname>Poussa</surname><given-names>T</given-names></name><name><surname>Sarnesto</surname><given-names>A</given-names></name><name><surname>Haahtela</surname><given-names>T</given-names></name><etal/></person-group><article-title>Probiotics in infancy induce protective immune profiles that are characteristic for chronic low grade inflammation</article-title><source>Clin EXP Allergy</source><year>2008</year><volume>38</volume><fpage>611</fpage><lpage>618</lpage><comment><uri xlink:type="simple" xlink:href="http://dx.doi.org/10.1111/j.1365-2222.2008.02942.x">http://dx.doi.org/10.1111/j.1365-2222.2008.02942.x</uri></comment><pub-id pub-id-type="pmid">18266878</pub-id></element-citation></ref><ref id="ref14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazloom</surname><given-names>Z</given-names></name><name><surname>Yousefinegad</surname><given-names>A</given-names></name><name><surname>Dabbaghmanesh</surname><given-names>M. H</given-names></name></person-group><article-title>Effect of probiotics on lipid profile, glycemic control, insulin action, oxidative stress and inflammatory markers in patients with type 2 diabetes: A clinical trail</article-title><source>IJMS</source><year>2013</year><volume>38</volume><issue>1</issue><fpage>38</fpage><lpage>43</lpage></element-citation></ref><ref id="ref15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musso</surname><given-names>G</given-names></name><name><surname>Gambino</surname><given-names>R</given-names></name><name><surname>Cassader</surname><given-names>M</given-names></name></person-group><article-title>Interactions between gut and host metabolism predisposing to obesity and diabetes</article-title><source>Ann Rev Med</source><year>2011</year><volume>62</volume><fpage>361</fpage><lpage>380</lpage><comment><uri xlink:type="simple" xlink:href="http://dx.doi.org/10.1146/annurev-med-012510-175505">http://dx.doi.org/10.1146/annurev-med-012510-175505</uri></comment><pub-id pub-id-type="pmid">21226616</pub-id></element-citation></ref><ref id="ref16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pickup</surname><given-names>J. C</given-names></name><name><surname>Mattock</surname><given-names>M. B</given-names></name><name><surname>Chusney</surname><given-names>G. D</given-names></name><name><surname>Burt</surname><given-names>D</given-names></name></person-group><article-title>NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X</article-title><source>Diabetologia</source><year>1997</year><volume>40</volume><fpage>1286</fpage><lpage>1292</lpage><comment>PMID PubMed: 9389420</comment><comment><uri xlink:type="simple" xlink:href="http://dx.doi.org/10.1007/s001250050822">http://dx.doi.org/10.1007/s001250050822</uri></comment><pub-id pub-id-type="pmid">9389420</pub-id></element-citation></ref><ref id="ref17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ray</surname><given-names>A</given-names></name><name><surname>Huisman</surname><given-names>M. V</given-names></name><name><surname>Tamsma</surname><given-names>J. T</given-names></name></person-group><article-title>The role of inflammation on atherosclerosis, intermediate and clinical cardiovascular endpoint in type 2 diabetes mellitus</article-title><source>Eur J Internal Med</source><year>2009</year><volume>20</volume><issue>3</issue><fpage>253</fpage><lpage>260</lpage><comment><uri xlink:type="simple" xlink:href="http://dx.doi.org/10.1016/j.ejim.2008.07.008">http://dx.doi.org/10.1016/j.ejim.2008.07.008</uri></comment><pub-id pub-id-type="pmid">19393492</pub-id></element-citation></ref><ref id="ref18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reaven</surname><given-names>G. M</given-names></name></person-group><article-title>Role of insulin resistance in human disease</article-title><source>Diabetes</source><year>1988</year><volume>37</volume><fpage>1595</fpage><lpage>1607</lpage><comment><uri xlink:type="simple" xlink:href="http://dx.doi.org/10.1016/S0899-9007(97)80637-5">http://dx.doi.org/10.1016/S0899-9007(97)80637-5</uri></comment><pub-id pub-id-type="pmid">3056758</pub-id></element-citation></ref><ref id="ref19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>P. M</given-names></name></person-group><article-title>Clinical application of c-reactive protein for cardiovascular disease detection and prevention</article-title><source>Circulation</source><year>2003</year><volume>107</volume><fpage>363</fpage><lpage>369</lpage><comment><uri xlink:type="simple" xlink:href="http://dx.doi.org/10.1161/01.CIR.0000053730.47739.3C">http://dx.doi.org/10.1161/01.CIR.0000053730.47739.3C</uri></comment><pub-id pub-id-type="pmid">12551853</pub-id></element-citation></ref><ref id="ref20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stehouwer</surname><given-names>C. D. A</given-names></name><name><surname>Gall</surname><given-names>M</given-names></name><name><surname>Twisk</surname><given-names>J. W. R</given-names></name><name><surname>Knudsen</surname><given-names>E</given-names></name><name><surname>Emeis</surname><given-names>J. J</given-names></name><name><surname>Parving</surname><given-names>H</given-names></name></person-group><article-title>Increased urinary albumin excretion, endothelial dysfunction and chronic low-grade inflammation in type 2 diabetes</article-title><source>Diabetes</source><year>2002</year><volume>51</volume><fpage>1157</fpage><lpage>1165</lpage><comment><uri xlink:type="simple" xlink:href="http://dx.doi.org/10.2337/diabetes.51.4.1157">http://dx.doi.org/10.2337/diabetes.51.4.1157</uri></comment><pub-id pub-id-type="pmid">11916939</pub-id></element-citation></ref><ref id="ref21"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Stenvinkel</surname><given-names>P</given-names></name><name><surname>Yeun</surname><given-names>Jy</given-names></name></person-group><person-group person-group-type="editor"><name><surname>kopple</surname><given-names>J. D</given-names></name><name><surname>Massry</surname><given-names>S. G</given-names></name></person-group><article-title>Role of inflammation in malnutrition and atherosclerosis in chronic renal failure</article-title><source>kopple Massry&#x02019;s nutritional management of renal disease</source><year>2004</year><publisher-loc>Philadelphia</publisher-loc><publisher-name>Lippicott, Williams Wilkins</publisher-name><fpage>199</fpage><lpage>212</lpage></element-citation></ref><ref id="ref22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steven</surname><given-names>M</given-names></name><name><surname>Haffner</surname><given-names>M. D</given-names></name><name><surname>Seppo Lehto</surname><given-names>M. D</given-names></name><name><surname>Tapani R&#x000f6;nnemaa</surname><given-names>M. D</given-names></name><name><surname>Kalevi Py&#x000f6;r&#x000e4;l&#x000e4;</surname><given-names>M. D</given-names></name><name><surname>Markku Laakso</surname><given-names>M. D</given-names></name></person-group><article-title>Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction</article-title><source>N Engl J Med</source><year>1998</year><volume>339</volume><fpage>229</fpage><lpage>234</lpage><comment><uri xlink:type="simple" xlink:href="http://dx.doi.org/10.1056/NEJM199807233390404">http://dx.doi.org/10.1056/NEJM199807233390404</uri></comment><pub-id pub-id-type="pmid">9673301</pub-id></element-citation></ref><ref id="ref23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voulgari</surname><given-names>Ch</given-names></name><name><surname>Tentolouris</surname><given-names>N</given-names></name><name><surname>Moyssakis</surname><given-names>I</given-names></name><name><surname>Dilaveris</surname><given-names>P</given-names></name><name><surname>Gialafos</surname><given-names>E</given-names></name><name><surname>Papadogiannis</surname><given-names>D</given-names></name><etal/></person-group><article-title>Spatial QRS-T angle: association with diabetes and left ventricular performance</article-title><source>Eur J Clin Invest</source><year>2006</year><volume>36</volume><fpage>608</fpage><lpage>613</lpage><comment><uri xlink:type="simple" xlink:href="http://dx.doi.org/10.1111/j.1365-2362.2006.01697.x">http://dx.doi.org/10.1111/j.1365-2362.2006.01697.x</uri></comment><pub-id pub-id-type="pmid">16919042</pub-id></element-citation></ref><ref id="ref24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>William</surname><given-names>B</given-names></name><name><surname>Kannel</surname><given-names>M. D</given-names></name><name><surname>Daniel</surname><given-names>L</given-names></name></person-group><article-title>Diabetes and cardiovascular disease. The Framingham study</article-title><source>JAMA</source><year>1979</year><volume>241</volume><fpage>2035</fpage><lpage>2038</lpage><comment><uri xlink:type="simple" xlink:href="http://dx.doi.org/10.1001/jama.1979.03290450033020">http://dx.doi.org/10.1001/jama.1979.03290450033020</uri></comment><pub-id pub-id-type="pmid">430798</pub-id></element-citation></ref><ref id="ref25"><element-citation publication-type="book"><collab>World Health Organization</collab><source>Diabetes mellitus. Report of WHO study group</source><year>1985</year><publisher-loc>Geneva</publisher-loc><comment>1985. (Tech. Rep. Ser No. 727)</comment></element-citation></ref></ref-list></back></article>